• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
Ke Lin, Dong Lei, Li Yue-qiang, Han Min. Clinical efficacy and safety ofbelimumab for lupus nephritis:a clinical observational study[J]. Journal of Clinical Nephrology, 2023, 23(2): 124-128. DOI: 10.3969/j.issn.1671-2390.2023.02.007
Citation: Ke Lin, Dong Lei, Li Yue-qiang, Han Min. Clinical efficacy and safety ofbelimumab for lupus nephritis:a clinical observational study[J]. Journal of Clinical Nephrology, 2023, 23(2): 124-128. DOI: 10.3969/j.issn.1671-2390.2023.02.007

Clinical efficacy and safety ofbelimumab for lupus nephritis:a clinical observational study

More Information
  • Received Date: September 14, 2022
  • Available Online: May 11, 2023
  • Published Date: February 27, 2023
  • Objective To observe the efficacy and safety of belimumab for lupus nephritis(LN) in real world.Methods For this retrospective and real-world clinical trial, 25 LN patients received belimumab from September 2020 to May 2022.Through comparing the changes in clinical parameters and observing adverse events before and after treatment, efficacy and safety of belimumab were observed.Results After a therapy of belimumab, anti-dsDNA antibody titer declined markedly(χ2=14.000, P=0.007) and complement C3 spiked sharply(F=3.228, P=0.0172) at different follow-up timepoints.After therapy, urinary protein-to-creatinine ratio(uPCR), urinary red blood cell count, SLEDAI score and dosage of oral corticosteroid dropped markedly and blood albumin and hemoglobin levels rose.And the differences were all statistically significant between baseline and values at Week 52.In addition, SLEDAI score(F=12.23, P<0.001) and dose of oral corticosteroid(F=13.57, P<0.001) were both statistically significant.During a therapy of belimumab, 6 patients reported such adverse events as infection(n=4) and leucopenia(n=2).All of them were cured and there was no onset of serious adverse events.Conclusions Belimumab is both safe and efficacious for LN.The occurrence of adverse events such as infection and leukopenia should be closely monitored during therapy.
  • [1]
    吴广礼.中国慢性肾脏病疾病谱的变迁及防治策略[J].中华医学信息导报, 2020, 35(24):20.DOI: 10.3760/cma.j.issn.1000-8039.2020.24.136.

    Wu GL.Changes of disease spectrum of chronic kidney disease in China and its prevention and treatment strategies[J].China Med News, 2020, 35(24):20.DOI: 10.3760/cma.j.issn.1000-8039.2020.24.136.
    [2]
    Gasparotto M, Gatto M, Binda V, et al.Lupus nephritis:clinical presentations and outcomes in the 21st century[J].Rheumatology(Oxford), 2020, 59(Suppl5):v39-v51.DOI: 10.1093/rheumatology/keaa381.
    [3]
    Mahajan A, Amelio J, Gairy K, et al.Systemic lupus erythematosus, lupus nephritis and end-stage renal disease:a pragmatic review mapping disease severity and progression[J].Lupus, 2020, 29(9):1011-1020.DOI: 10.1177/0961203320932219.
    [4]
    王金润, 吴雪, 迪丽尼戈尔·艾克拜, 等.贝利尤单抗治疗系统性红斑狼疮的疗效和安全性研究[J].中华风湿病学杂志, 2021, 25(8):529-532.DOI: 10.3760/cma.j.cn141217-20210218-00061.

    Wang JR, Wu X, Diliniger·Aikebai, et al.Efficacy and safety of belimumab in the treatment of systemic lupus erythematosus[J].Chin J Rheumatol, 2021, 25(8):529-532.DOI: 10.3760/cma.j.cn141217-20210218-00061.
    [5]
    Blair HA, Duggan ST.Belimumab:areview in systemic lupus erythematosus[J].Drugs, 2018, 78(3):355-366.DOI: 10.1007/s40265-018-0872-z.
    [6]
    Ward M, Tektonidou MG.Belimumab as add-on therapy in lupus nephritis[J].N Engl J Med, 2020, 383(12):1184-1185.DOI: 10.1056/NEJMe2027516.
    [7]
    Depascale R, Gatto M, Zen M, et al.Belimumab:a step forward in the treatment of systemic lupus erythematosus[J].Expert Opin Biol Ther, 2021, 21(5):563-573.DOI: 10.1080/14712598.2021.1895744.
    [8]
    谢文慧, 张卓莉.贝利尤单抗治疗系统性红斑狼疮:现状与展望[J].中华风湿病学杂志, 2020, 24(7):495-499.DOI: 10.3760/cma.j.c141217-20191213-00420.

    Xie WH, Zhang ZL.Belimumab for systemic lupus erythematosus:current status and prospects.DOI: 10.3760/cma.j.c141217-20191213-00420.
    [9]
    徐甜, 施璇, 谢筱彤, 等.贝利尤单抗在一例活动性狼疮肾炎年轻女性患者中的应用[J].中华肾脏病杂志, 2021, 37(4):366-368.DOI: 10.3760/cma.j.cn441217-20200707-00053.

    Xu T, Shi X, Xie XT, et al.Efficacy of belimumab for active lupus nephritis in a young woman[J].Chin J Nephrol, 2021, 37(4):366-368.DOI: 10.3760/cma.j.cn441217-20200707-00053.
    [10]
    Yu XQ, Chen N, Xue J, et al.Efficacy and safety of belimumab in patients with lupus nephritis:subgroup analyses of a phase 3 randomized trial in the east Asian population[J].Am J Kidney Dis, 2022 DOI: 10.1053/j.ajkd.2022.06.013.
    [11]
    Rovin BH, Furie R, Teng YKO, et al.A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J].Kidney Int, 2022, 101(2):403-413.DOI: 10.1016/j.kint.2021.08.027.
    [12]
    Navarra SV, Guzmán RM, Gallacher AE, et al.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial[J].Lancet, 2011, 377(9767):721-731.DOI:10.1016/S0140-6736(10) 61354-2.
    [13]
    Fanouriakis A, Kostopoulou M, Cheema K, et al.2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association(EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J].Ann Rheum Dis, 2020, 79(6):713-723.DOI: 10.1136/annrheumdis-2020-216924.
    [14]
    张辉, 杨念生, 鲁静, 等.狼疮肾炎诊疗规范[J].中华内科杂志, 2021, 60(9):784-790.DOI: 10.3760/cma.j.cn112138-20210609-00410.

    Zhang H, Yang NS, Lu J, et al.Recommendations for the diagnosis and management of lupus nephritis in China[J].Chin J Intern Med, 2021, 60(9):784-790.DOI: 10.3760/cma.j.cn112138-20210609-00410.
    [15]
    Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, ChineseSystemic Lupus Erythematosus Treatment and Research Group.2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J].Chin J Intern Med, 2020, 59(3):172-185.DOI: 10.3760/cma.j.issn.0578-1426.2020.03.002.
    [16]
    Furie R, Rovin BH, Houssiau F, et al.Two-year, randomized, controlled trial of belimumab in lupus nephritis[J].N Engl J Med, 2020, 383(12):1117-1128.DOI: 10.1056/NEJMoa2001180.
    [17]
    Gatto M, Saccon F, Andreoli L, et al.Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting(BeRLiSS-LN).Results from a large, nationwide, multicentric cohort[J].J Autoimmun, 2021, 124:102729.DOI: 10.1016/j.jaut.2021.102729.
    [18]
    von Kempis J, Duetsch S, Reuschling N, et al.Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings:a retrospective analysis of results from the OBSErve study in Switzerland[J].Swiss Med Wkly, 2019, 149:w20022.DOI: 10.4414/smw.2019.20022.
    [19]
    Collins CE, Dall'Era M, Kan H, et al.Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings:24-month results from the OBSErve study in the USA[J].Lupus Sci Med, 2016, 3(1):e000118.DOI: 10.1136/lupus-2015-000118.
    [20]
    Wise LM, Stohl W.The safety of belimumab for the treatment of systemic lupus erythematosus[J].Expert Opin Drug Saf, 2019, 18(12):1133-1144.DOI: 10.1080/14740338.2019.1685978.
    [21]
    Wallace DJ, Ginzler EM, Merrill JT, et al.Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J].Arthritis Rheumatol, 2019, 71(7):1125-1134.DOI: 10.1002/art.40861.
    [22]
    van Vollenhoven RF, Navarra SV, Levy RA, et al.Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab:a Phase Ⅲ study extension[J].Rheumatology(Oxford), 2020, 59(2):281-291.DOI: 10.1093/rheumatology/kez279.

Catalog

    Article views (323) PDF downloads (98) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return